<DOC>
	<DOCNO>NCT00999128</DOCNO>
	<brief_summary>This Phase I , randomize , two-part , single-center pharmacokinetics ( PK ) study assess relative bioavailability capsule tablet formulation GDC-0941 fast state ( Part 1 ) determine effect food proton pump inhibition PK tablet formulation GDC-0941 ( Part 2 ) . Approximately 18 subject enrol Part 1 32 subject enrol Part 2 . Subjects participate Part 1 eligible participate Part 2 .</brief_summary>
	<brief_title>A Study Determine Relative Bioavailability Capsule Tablet Formulations GDC-0941 Effect Food Proton Pump Inhibition GDC-0941 Tablet Pharmacokinetics Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rabeprazole</mesh_term>
	<criteria>Inclusion Criteria Male female , 18 65 year age , inclusive ( Part 1 ) Male female , 18 45 year age , inclusive ( Part 2 ) In good health , determine clinically significant finding medical history , 12lead electrocardiogram ( ECG ) , vital sign assessment Body Mass Index ( BMI ) 1830 kg/m^2 inclusive , body weight &gt; 50 kg Clinical laboratory evaluation within reference range test laboratory Negative test select drug abuse screening ( include alcohol ) checkin ( include alcohol ) Negative HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody screen Agreement use effective form contraception duration study Exclusion Criteria History clinical manifestation significant metabolic ( include type 1 2 diabetes ) , hepatic , renal , hematological , pulmonary , cardiovascular , endocrine , gastrointestinal , urological , neurological , psychiatric disorder , cancer History inflammatory arthritis History symptomatic hypotension History severe physical injury , direct impact trauma , neurological trauma within specify timeframe prior Day 1 History seizure disorder History bipolar major depressive disorder History stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug ( exception : appendectomy , hernia repair , and/or cholecystectomy ) History presence abnormal ECG Subjects history ventricular dysrhythmias risk factor ventricular dysrhythmias History alcoholism , drug abuse , drug addiction Use nicotinecontaining nicotinereplacement product within specify timeframe prior Day 1 Participation investigational study drug trial receipt investigational study drug occur within specify timeframe prior Day 1 Use prescription medications/products within specify timeframe prior Day 1 ( exception : hormone replacement therapy [ HRT ] , oral , implantable , transdermal contraception ) Receipt vaccination immunization within specify timeframe prior Day 1 Use proton pump inhibitor H2receptor antagonist within specify timeframe prior Day 1 Known hypersensitivity rabeprazole component , derive product benzimidazoles Use overthecounter ( OTC ) , nonprescription preparation within specify timeframe prior Day 1 Use alcoholcontaining , grapefruitcontaining , caffeinecontaining food beverage within specify timeframe prior Day 1 Poor peripheral venous access Donation blood plasma within specify timeframe prior Day 1 Receipt blood product within specify timeframe prior Day 1 Vegetarians unable consume highfat meal Women pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>PI3K inhibitor</keyword>
	<keyword>PI3 kinase</keyword>
	<keyword>PI3 kinase inhibitor</keyword>
</DOC>